Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Sep 1;1(1):119-141.
doi: 10.1146/annurev-virology-031413-085442.

Oncolytic Poxviruses

Winnie M Chan  1 , Grant McFadden  1
Affiliations

Oncolytic Poxviruses

Winnie M Chan et al. Annu Rev Virol. .

Abstract

Current standard treatments of cancer can prolong survival of many cancer patients but usually do not effectively cure the disease. Oncolytic virotherapy is an emerging therapeutic for the treatment of cancer that exploits replication-competent viruses to selectively infect and destroy cancerous cells while sparing normal cells and tissues. Clinical and/or preclinical studies on oncolytic viruses have revealed that the candidate viruses being tested in trials are remarkably safe and offer potential for treating many classes of currently incurable cancers. Among these candidates are vaccinia and myxoma viruses, which belong to the family Poxviridae and possess promising oncolytic features. This article describes poxviruses that are being developed for oncolytic virotherapy and summarizes the outcomes of both clinical and preclinical studies. Additionally, studies demonstrating superior efficacy when poxvirus oncolytic virotherapy is combined with conventional therapies are described.

Keywords: myxoma virus; oncolytic; vaccinia virus; virotherapeutics; virotherapy; virus tropism.

PubMed Disclaimer

References

    1. Breitbach CJ, Reid T, Burke J, Bell JC, Kirn DH. Navigating the clinical development landscape for oncolytic viruses and other cancer therapeutics: no shortcuts on the road to approval. Cytokine Growth Factor Rev. 2010;21:85–89. - PubMed
    1. Donnelly O, Harrington K, Melcher A, Pandha H. Live viruses to treat cancer. J. R. Soc. Med. 2013;106:310–314. - PMC - PubMed
    1. Donnelly OG, Errington-Mais F, Prestwich R, Harrington K, Pandha H, et al. Recent clinical experience with oncolytic viruses. Curr. Pharm. Biotechnol. 2012;13:1834–1841. - PubMed
    1. Eager RM, Nemunaitis J. Clinical development directions in oncolytic viral therapy. Cancer Gene Ther. 2011;18:305–317. - PubMed
    1. Miest TS, Cattaneo R. New viruses for cancer therapy: meeting clinical needs. Nat. Rev. Microbiol. 2014;12:23–34. - PMC - PubMed
-